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ABSTRACT 
 
Nontuberculous mycobacteria (NTM) are categorized as one of the large and diverse groups of 
environmental organisms which are abundant in water and soil. NTM cause a variety of diseases in 
humans that mainly affect the lung. A predisposition to pulmonary NTM is evident in patients with 
parenchymal structural diseases including bronchiectasis, emphysema, tuberculosis (TB), cystic 
fibrosis (CF), rheumatologic lung diseases and other chronic diseases with pulmonary 
manifestations. Lung infections are not the only consequences of being infected by NTM as they 
can also infect skin and soft tissue and may also cause lymphadenitis (predominantly in young 
children) and disseminated disease in human immunodeficiency virus (HIV)-infected patients or 
those with severely compromised immune system. NTM are also found in many subjects without 
any known risk factors. Although the recent advances in imaging and microbiologic techniques 
including gene sequencing have provided a better view of the problems caused by NTM and has 
enhanced our understanding of the disease, many uncertainties regarding the immunologic response 
to NTM still exist. There is also limited data on the immunogenetics of NTM infection. Here, the 
authors reviewed the main immunogenetic defects as well as other immunological conditions which 
are associated with an increased the risk of NTM infections. 
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INTRODUCTION 
 
For a long time, nontuberculous mycobacteria 
(NTM) were considered as environmental organisms of 
limited clinical relevance.  Population-based data 
regarding the incidence of lung diseases caused by 
NTM was scarce with voluntary-reported rates of 0.7 to 
1.8 cases annually per 100,000 people worldwide.
1
 
However, in the past decade, the prevalence of NTM in 
the aged population has been shown to be significant 
being even higher than that of tuberculosis (TB) in the 
US.
2-4
  
The general healthcare community recognized the 
importance and significance of disseminated 
Mycobacterium (M.) avium and M. intracellulare as 
major NTM infections during the human 
immunodeficiency virus (HIV) pandemic and the 
expansion of iatrogenic immunosuppression confirmed 
their infectious role.
5
 The risk of NTM infection is 
increased in subjects with an abnormal immune system. 
For instance, a powerful anti- interferon (IFN)- 
activity within plasma was attributed to the existence of 
high affinity IFN- neutralizing autoantibodies in a 
patient with severe M. cheloneae infection.
6
 Other 
studies have linked the presence of anti-IFN- 
antibodies to disease progression.
7,8
 This indicates the 
clinical importance of immune dysregulation, which 
could lead to NTM infection. 
Reports of the clinical significance of NTM isolates 
from lung specimens are variable. The highest rates 
reported are in the United States
2-4
 and the most scarce 
epidemiologic data are available from Asian countries.
9
 
This may reflect the presence of many undiagnosed 
cases and the lack of documented data in countries with 
less sophisticated and organized healthcare systems.  
For instance, in South Korea, approximately 25% of 
patients from whom NTM, mainly M. avium complex 
and M. abscessus, were isolated showed clinical NTM 
lung infections with variable severities. These 
infections ranged from upper lobe cavitary 
manifestations to less severe clinical forms.
9
 In eastern 
China, NTM comprised 60% of all smear positive 
clinical isolates with M. intercellulare being the most 
prevalent species of clinical importance.
2
 A meta-
analyses conducted in Iran, reported the prevalence of 
NTM to be 10.2% among culture positive tuberculosis 
cases with M. simiae, M. intracellulare, and M. 
fortuitum, being the most prevalent species.
10
 Another 
study by the same team showed that 30% of multi-drug 
resistant TB patients had NTM and showed pulmonary 
signs of NTM infection.
11
 The major underlying causes 
and risk factors among the studied patients included 
malignancies, organ transplantation and infection with 
HIV which all indicated the presence of direct or/and 
indirect immunosuppression.
11
   
The environmental prevalence of NTM in the 
suburbs of Tehran is linked to the species isolated from 
clinical specimens with the most prevalent species 
being M. farcinogens and M. fortuitum.
12
 These 
regional differences in both the prevalence of NTM 
infections and the major strains contributing to disease 
manifestations may reflect the importance of NTM 
infections in each geographical region. This provides 
opportunities for designing appropriate management 
measures to control the clinical burden of the disease. 
The present paper is a general overview of the major 
immunogenetic defects as well as other immunological 
conditions contributing to an increased risk of NTM 
infections.   
 
NTM Infection in Immunocompromised Patients 
The most prominent human factors that predispose 
humans to NTM can be classified into two main 
categories: pre-existing structural lung disease and 
patients with one or more of a variety of genetic defects 
in cell-mediated immune pathways.
13
 The second group 
of factors all cause an immunocompromising state 
giving rise to a defective immune response against 
NTM.  These factors include interleukin (IL)-12/IFN-γ 
axis abnormalities, association with certain HLAs, 
autosomal and X-linked mutations and polymorphisms 
of several genes whose function is important in 
macrophage function.
13,14
 We summarize here some of 
the most important of these immunological factors.  
 
Primary and Secondary Immunodeficiency Patients 
NTM is more prevalent in primary and secondary 
immune deficiency disorders (Figure 1). Mendelian 
susceptibility to M. tuberculosis (MSMD) is a primary 
immunodeficiency in which patients bear mutations in 
critical cytokine pathways such as IL-12B, the IL-12 
receptor (IL-12R) β1 or the IFN- receptors (IFN-
R)115-17 and IFN-R2 predisposing them to NTM 
infection.
18
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Figure 1. Important predisposing factors of nontuberculous mycobacteria (NTM). Primary and secondary 
immunodeficiencies, immunosuppressive agents and graft versus host disease following hematopoietic stem cell 
transplantation predispose individuals to NTM infections.  Moreover, chronic obstructive pulmonary disease, cystic fibrosis, 
non-CF bronchectasia, diabetes mellitus and concurrent infection with mycobacterium tuberculosis are risk factors for NTM.  
NTM infection has a range of manifestations including pulmonary, cutaneous, ocular, disseminated disease (mainly in HIV 
positive patients) and NTM-induced osteomyelitis. Cosmetic procedures are also a risk factor for NTM.  The major species 
responsible for infection at each site are shown.  
NTM, Non-tuberculous Mycobacteria; PID, Primary Immunodeficiency; MSMD, Mendelian Susceptibility for Mycobacterial 
Disease; CGD, Chronic Granulomatous Disease; SCID, Severe Combined Immunodeficiency; SID, Secondary 
Immunodeficiency; HIV, Human Immunodeficiency Virus; CLL, Chronic Lymphocytic Leukemia; GVHD, Graft Versus 
Host Disease; COPD, Chronic Obstructive Pulmonary Disease; CF, Cystic Fibrosis.     
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Mutations in the transcription factor STAT1
19-21
 
results in a failure to respond to signals from type I 
(IFNα/β), type II (IFN-) and type III (IFNλ1/ 2/3) 
interferons resulting in an enhanced risk of 
mycobacterial and viral infections. A similar effect is 
seen in subjects with a deficiency in tyrosine kinase 2 
(TYK2), a janus kinase widely active in cytokine 
signaling. Tyk2 depletion prevents signaling from the 
IL-12-IL-12Rβ1 complex resulting in defective control 
of mycobacterial infection.
22
 Production of IL-12 in 
response to IFN- is hindered by mutations in 
interferon regulatory factor (IRF)-8
23
 and mutations in 
interferon stimulated gene (ISG)-15 confers 
susceptibility to NTM.
24
 NTM susceptibility is also 
caused by a deficiency in nuclear factor‐κB essential 
modulator (NEMO). This implicates NF-κB and, by 
extrapolation, its upstream drivers tumour necrosis 
factor (TNF) and/or signaling via Toll-like receptors 
(TLRs) in NTM infection.
25,26
 An increase in local 
and/or systemic complications following vaccination 
with bacillus Calmette-Guérin (BCG) is seen in some 
primary immunodeficiencies such as chronic 
granulomatous disease (CGD).
27
 A defect in 
mononuclear phagocytes is the simplest explanation for 
NTM susceptibility although several other factors such 
as natural killer (NK) cell deficiency and impaired 
cytokine release have also been evoked.
28-30
 A 
significant risk of NTM infection is found with 
autosomal dominant deficiency of the transcription 
factor GATA-2.
31
  
Patients with immunodeficiencies that profoundly 
affect the number or function of T cells are at risk of 
NTM infection as well as by many other intracellular 
pathogens. This includes severe combined immune 
deficiency (SCID)
32
 and isolated CD4+ T cell 
deficiency
33
 which is associated with both pulmonary 
and disseminated NTM infection. HIV infection, 
especially in patients with CD4+ T cell counts of less 
than 50/μl of blood, is associated with the considerable 
proportion of NTM infections seen in secondary 
immunodeficiencies.
34
 Based on the type and severity 
of immunosuppression, the symptoms and 
manifestation of NTM pulmonary disease vary among 
immunosuppressed patients. Mycobacterium avium 
complex (MAC) are the most common species isolated 
from NTM patients in the US.
35
 They are also the most 
common cause for the disseminated NTM disease in 
patients with systemic immunosuppression (e.g. HIV 
infection) and severe CD4 cell depletion.
35
 Historically, 
43% of AIDS patients had disseminated NTM 
infections, defined as NTM isolation from either blood 
or mesenteric lymph nodes on autopsy, in the pre-anti-
retroviral therapy (ART) era.
36
 
NTM affects the respiratory system irrespective of 
whether it is due to primary or secondary infection. 
Pulmonary disease in the form of a single NTM 
manifestation, is rare in HIV patients, and is present in 
only 2.5% of 200 patients with disseminated MAC 
infection. Recently, Amran et al. reported the presence 
of elevated levels of cytomegalovirus (CMV) 
antibodies in plasma from patients with stable 
pulmonary NTM disease. Higher levels of CMV 
antibodies in NTM patients may be an indication of 
frequent episodes of CMV reactivation. This suggests 
that NTM patients may have CMV end-organ disease 
but they often experience non-specific symptoms 
(fever, malaise, etc) consistent with CMV 
reactivation.
37
 
 
Haematological Malignancies 
There is evidence of an increased prevalence of 
NTM infection in patients with hematological 
malignancies. The mean prevalence of NTM infection 
is 1.2% in patients with hematological malignancies 
whilst it ranged from 0.3% to 3.8% in patients with 
myeloma and chronic lymphoid leukemia 
respectively.
38
 In addition, the incidence of NTM 
infection among hematopoietic stem cell recipients 
ranges from 0.4% to 4.9%.
39-42
 These rates are far 
higher than the prevalence rate in the normal 
population
34-46
 and suggest that NTM may be an 
opportunistic infection in patients with hematological 
malignancies. 
 
Anti-TNF-α Therapy 
A dramatic increase in the number of NTM reports 
has been associated with anti–TNF-α therapy.47 The 
majority of patients with anti–TNF-α–related NTM 
were elderly women suffering from rheumatoid arthritis 
(RA).  Several factors may explain these findings. 
Firstly, RA is the most prevalent autoimmune 
inflammatory disease for which anti–TNF-α therapies 
have been used.
48
 Approximately 0.5%–1.0% of the US 
population suffer from RA
49,50
 and almost 40% of these 
are on anti-TNF- therapy.48 Secondly, about 10% of 
RA patients suffer from rheumatoid lung disease which 
causes bronchiolitis and bronchiectasis which are 
known risk factors for NTM disease.
51
 Moreover, 
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pulmonary NTM disease and RA are more common 
among women older than 50 irrespective of anti–TNF-
α therapy.1 Finally, a high percentage of patients 
receiving anti–TNF-α therapy may have serious co-
morbid conditions that increase the risk of NTM 
infection.
52
  
The risk of pulmonary and disseminated TB is 
increased using TNF-α inhibitors53,54 and consequently 
this may also increase the risk for NTM disease 
following TB-induced remodeling.
55-57
 Despite 
aggressive anti-mycobacterial treatment, pulmonary 
NTM disease progressed in TB patients whilst they 
were receiving anti–TNF-α therapy.58 Although this 
can lead to serious sickness and even death, the safety 
of continuing anti–TNF-α therapy during anti-
mycobacterial therapy needs clarification. Furthermore, 
the timing of when, or if, it is safe to restart anti–TNF-α 
therapy in such patients is unclear.  
 
Defective IL-12-IFN-γ Axis 
The IFN-γ–IL-12 axis is another important player in 
controlling mycobacteria as well as other opportunistic 
pathogens.
59
 High-titer neutralizing anti–IFN-γ 
autoantibodies cause a syndrome of disseminated NTM 
and other opportunistic infections which may be 
prevented by anti-CD20 (rituximab) treatment.
60-61
 
MSMD is a state of predisposition to weakly virulent 
mycobacteria as well as other pathogens such as 
salmonella, and is linked with mutations in the genes 
involved in the IL-12/IFN-γ axis. These include 
different components of the IFN-γ receptor (IFNGR) 
downstream signaling pathways.
62,63
 Based on the type 
of inheritance pattern and the affected component, 
which are mainly due to IFNGR1 and IFNGR2 genes, 
partial or complete deficiencies may arise.
63
 
 
Other Risk Factors for NTM Infection 
Age increases the susceptibility to pulmonary NTM 
(p-NTM) disease with the mean age at presentation in 
the US being 68.2 years.
64
 In addition, the prevalence 
of pulmonary NTM is greater in females than in 
males
65-67
 and females with non-CF bronchiectasis had 
the highest risk.
68,69
 Experiments in ovariectomised 
mice showed that estrogen enhances the clearance of 
MAC and the greater susceptibility of females may be 
because of low post-menopausal estrogen levels.
70
 
However, this has not been supported conclusively in 
humans.
5,71
  
Severe vitamin D deficiency may also contribute to 
pulmonary NTM disease.
72
 There is a link with vitamin 
D receptor (VDR) polymorphisms but, overall, the 
mechanism is not as clear as it is for M. tuberculosis.
73-
76
 A systematic review showed that the prevalence of 
NTM disease is increasing as the burden of TB 
declines.
47
 This may reflect NTM being misdiagnosed 
as TB.  In a previous study on 27 subjects with multi-
drug resistant TB (MDR-TB) in Iran, our team reported 
NTM in 10%-30% of subjects with suspected MDR-
TB.
10,77
 The financial burden imposed both on the 
patient and the healthcare system necessitates 
considering NTM infections in every patient with 
suspected MDR-TB.     
 
NTM Infection Manifestations 
NTM Pulmonary Disease 
Multiple isolates of NTM species from respiratory 
secretions might be indicative of true disease. 
Haematopoietic stem cell and solid organ transplant 
(SOT) recipients are in risk for pulmonary NTM with 
an incidence rate of 0.2–5%.68,78,79 Pulmonary infection 
resulted from rapidly growing mycobacteria is the most 
common NTM infection among stem cell transplant 
recipients. NTM is also the second most common cause 
of catheter-related infections in this group of patients.
78
 
Graft versus host disease is a risk factor for NTM 
which mainly occurs within the first half-year post-
transplantation. A high mortality rate occurs in organ 
transplant patients with NTM pulmonary disease.  For 
instance, there is a 3-year mortality rate of 69% in 
patients with M. xenopi pulmonary disease in a French 
cohort.
80
  
However, other factors such as NTM disease 
severity, the precise NTM species,
81,82
 patient age and 
underlying comorbidities may explain the poor 
outcome and mortality in lung transplant recipients 
compared to hematologic malignancies (lung, 15 
months; kidney, 24 months; heart, 30 months).
78
 NTM 
treatment should be instituted according to published 
guidelines.
67,68
 Drug interactions between antibiotics 
and immunosuppressive agents pose a potential risk 
and patients should be closely monitored for side 
effects.
68,83
  
 
NTM Cutaneous Disease 
After pulmonary disease, skin and soft tissues are 
the organs most commonly affected by NTM. Almost 
all NTM species can cause cutaneous infections, 
however, some species such as M. marinum, M. 
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abscessus, M. fortuitum and M. chelonae are most 
common.
84
 Infectious post-operational complications 
are among the major adverse effects associated with 
cosmetic surgery.
85
 Disruption of the skin barrier is 
necessary for NTM to cause infection and ablative 
resurfacing using lasers provides an ideal opportunity 
for saprophytic NTM to penetrate this barrier.  
Although uncommon, NTM infections constitute a 
considerable proportion of skin infections.
86
   
The presence of anti-IFN-γ auto-antibodies causing 
adult immunodeficiencies can result in disseminated 
NTM infections.  These might also manifest as reactive 
dermatological conditions such as the sweet`s 
syndrome, a type of neutrophil-mediated dermatosis.
87
 
 
NTM-Induced Osteomyelitis 
Defects in the IFN-γ-IL-12 axis, infection or other 
immunocompromising conditions enable disseminated 
NTM infections to occur in the skeletal system and 
joints. Although the prognosis is poor and the 
pathogenesis is not yet well-understood, long-term 
antibiotic therapy using combinations of drugs has 
improved the outcome of NTM-induced 
osteomyelitis.
88
  
 
NTM Ocular Disease 
Despite a few early reports of NTM-related ocular 
conditions such as choroid plexus inflammation and 
endophthalmitis, the emergence of laser-assisted in situ 
keratomileusis (LASIK) has resulted in a noticeable 
increase in the number of NTM-related keratitis 
cases.
89
 NTM infections of the eye target a number of 
structures resulting in ocular, intraocular and periocular 
infections as well as keratitis and uveitis. Early 
diagnosis of NTM infections of the eye is a constant 
challenge for clinicians and despite being uncommon, 
delayed diagnosis can be highly detrimental to the 
patient. The most common species involved are M. 
chelonae, M. abscessus, and M. fortuitum.
90 
 
Future Directions and Perspectives 
The mechanism(s) by which the human immune 
system responds to NTM is still unclear. Further 
investigations are required to determine the role of 
genetics in enabling NTM infections. Functional 
mutations due to single nucleotide polymorphisms in 
immune genes may be responsible for the increased 
susceptibility to NTM even in patients with underlying 
pulmonary diseases including COPD.  
Concluding Remarks 
NTMs are associated with a number of lung 
disorders particularly in patients with bronchiectasis, 
emphysema, TB, cystic fibrosis and with other chronic 
diseases such as RA. The compromised immune system 
is the pivotal risk factor giving rise to NTM infections. 
This can be the result of primary defects in the main 
pathways of the immune system as well as secondary 
causes of immunosuppression. Secondary causes 
include the use of immunosuppressive drugs, 
infections, and any other conditions that might 
contribute to a weakened immune response against 
mycobacterial infections, The infection is disseminated 
in HIV-infected patients or those with severely 
compromised immune systems.  A major challenge for 
both clinicians and researchers is the lack of a 
definitive immune mechanism that drives the
 
predisposition
 
to
 
NTM
 
disease. The changing pattern of 
infections in many regions from TB to NTM highlights 
the importance of NTM infections as a clinical concern. 
More research into the epidemiology and immunology 
of NTM is required to enable improvements in clinical 
management. Moreover, identification of the infective 
species in individuals from different regions where 
NTM is prevalent may aid in the early diagnosis of 
NTM disease.   
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